Q2 FY24 Financial Highlights
India: Outperforming market growth
India Region Formulations (IRF) has grown 8.9% ex
NLEM impact in Q2FY24
Leveraging therapy leadership by adding 7
new divisions in last 12 months
India Sales (INR mn)
16,915
16,384
15,841
15,213
14,786
#2 rank
Respiratory
#3 rank
#3 rank
Diabetes Care
Cardiac
•
7,250 Total ME's and 9,440 total sales force
.
Addition of new diabetic division in Q2FY24
Q2FY23 Q3FY23 Q4FY23 Q1FY24
Q2FY24
LUPIN
.
Continued Outperformance in Cardiac and Respiratory
therapies
Non-IL portfolio grew 9.2% in Q2 vs IPM growth of 7%¹
Key segments including Cardiology, Respiratory, Gl and
Gynaecology grew faster than market
• Anti-diabetes Non-IL growth 10% vs IPM 4.9% growth¹
•
In-licensed % of India sales: 13% Q2 vs 15.5% in FY23
Gaining significant launch momentum with 4 new
introductions in the quarter
Key New Launches
0
* 1 in
Diabetes Care
1 in
Derma
1
Vaccine
1 in
GI
• Valentas® Ranked #1 new launch in Cardiac²
1 IQVIA July-Sep 23
2 IQVIA MAT Sep-23
•
Poised to launch 20+ products in FY24
7View entire presentation